Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Harbour Biomed Approved for China Phase II/III Trials of Graves' Ophthalmopathy Treatment

publication date: Jun 2, 2020

Harbour Biomed announced that China's NMPA approved its IND application to conduct a Phase II/III trial of HBM9161 in patients with Graves’ ophthalmopathy, an autoimmune disorder. HBM9161 is a fully-human antibody targeting neonatal Fc receptor (FcRn) that HBM in-licensed from Korea's HanAll Biopharma. The IND approval is the fourth for HBM9161 in China and the second to allow HBM to proceed directly to Phase III under an accelerated pathway. HBM is headquartered in Cambridge, MA, with drug discovery operations in the Netherlands and R&D laboratories in Suzhou. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital